A PHASE III TRIAL EVALUATING THE ROLE OF CONTINUOUS LETROZOLE VERSUS INTERMITTENT LETROZOLE FOLLOWING 4 TO 6 YEARS OF PRIOR ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE-RECEPTOR POSITIVE, NODE POSITIVE EARLY STAGE BREAST CANCER

Trial Profile

A PHASE III TRIAL EVALUATING THE ROLE OF CONTINUOUS LETROZOLE VERSUS INTERMITTENT LETROZOLE FOLLOWING 4 TO 6 YEARS OF PRIOR ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE-RECEPTOR POSITIVE, NODE POSITIVE EARLY STAGE BREAST CANCER

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLE
  • Sponsors Novartis
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 18 Sep 2014 Planned primary completion date changed to 1 Dec 2021.
    • 12 Sep 2012 New source identified and integrated (University Hospital Medical Information Network - Japan; UMIN000004458).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top